Collaborative work unravels hidden molecular secrets of age-related diseases
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, and the University of Copenhagen announced today the release ...
Tag: Drug Discovery
Phase 2 clinical trial of DS-1211 begins for individuals with Pseudoxanthoma Elasticum
A Phase 2 clinical trial has started of DS-1211 in individuals with Pseudoxanthoma Elasticum (PXE), a rare multisystem genetic disease ...
Augmented drug preferentially eliminates cancer cells but does not harm healthy cells
Johns Hopkins Medicine researchers have revamped an anti-cancer drug to better target cancer cells and leave healthy tissues unharmed. Scientists ...
Harnessing the natural potential of venom for drug discovery
Venoms, found in many species of reptiles, invertebrates, and even fish, are typically known for their ability to cause periods ...
Exploring new therapeutic targets and biomarkers for neurodegenerative disorders
In this interview, Dr. Shebna Massey discusses neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, and more. She also discusses and ...
Two small molecules reverse pancreatic acinar ductal metaplasia
Pancreatic cancer often lurks as a silent disease. With no known symptoms, it can progress undetected and spread to other ...
Viagra and Cialis may not be suitable candidates for treating dementia, NIH DREAM study shows
Results from the National Institutes of Health's Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study show that sildenafil (Viagra) and ...
Small antiviral molecules termed assembly modulators show therapeutic efficacy against cancer
In a recent study posted to the bioRxiv* server, researchers evaluated the anti-cancer therapeutic efficacy of two structurally-unrelated small molecules, ...
Universal vaccine advancement through AI and recombinant technology
In this interview, NewsMedical talks to Dr. Amy Sheng, a technical account manager at Sino Biological, and Dr. Lurong Pan, ...
Producing complex samples and effective solutions for the fight against disease
Creoptix, the newest branch of the Malvern Panalytical portfolio, is focused closely on bioanalytical analysis. Closely collaborating with drug development ...